![Frederic Schynts](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Dominique Surleraux | M | - |
BCI Pharma SAS
![]() BCI Pharma SAS Miscellaneous Commercial ServicesCommercial Services BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | 11 years |
Benjamin Damien | M | - |
Sagitta Biotech SA
![]() Sagitta Biotech SA Miscellaneous Commercial ServicesCommercial Services Sagitta Biotech SA provides research and development of biotechnology. The company is based in Liege, Belgium. The Belgian company was founded in 2019. Benjamin Damien has been the CEO of the company since 2019. | 5 years |
Elisabeth Picou | M | - |
BCI Pharma SAS
![]() BCI Pharma SAS Miscellaneous Commercial ServicesCommercial Services BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | 11 years |
Didier Malherbe | M | - |
BCI Pharma SAS
![]() BCI Pharma SAS Miscellaneous Commercial ServicesCommercial Services BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | 4 years |
Jean-Marc Legrand | M | - |
BCI Pharma SAS
![]() BCI Pharma SAS Miscellaneous Commercial ServicesCommercial Services BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | 7 years |
Didier Allaer | M | - |
Sagitta Biotech SA
![]() Sagitta Biotech SA Miscellaneous Commercial ServicesCommercial Services Sagitta Biotech SA provides research and development of biotechnology. The company is based in Liege, Belgium. The Belgian company was founded in 2019. Benjamin Damien has been the CEO of the company since 2019. | 1 years |
Cyril Dousson | M | - |
BCI Pharma SAS
![]() BCI Pharma SAS Miscellaneous Commercial ServicesCommercial Services BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | 3 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
France | 5 | 71.43% |
Belgium | 2 | 28.57% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Frederic Schynts
- Personal Network